Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled study of minodronate in postmenopausal women with osteoporosis
ChiCTR1800017250Phase 3Completed
- Sponsor
- Peking University First Hospital
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minodronic acid in osteoporosis (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Percent change in average lumbar spine bone mineral density from baseline to week 48. Started May 2015; status: completed.
02
Drugs
minodronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR1800017250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017250.